Heart Failure Start-Ups Balance High-Risk, High-Reward Opportunity
Medtech start-ups are pioneering innovative device solutions for heart failure that they hope will end the vicious cycle of costly hospitalizations and declining patient health. Profiles of Calon-Cardio Technology, Cibiem, and DC Devices.
You may also be interested in...
BioVentrix Inc. has its sights set on US market approval for its hybrid transthoracic-endovascular Revivent-TC system, a unique device that enables a minimally invasive approach to treating patients who develop ischemic heart failure following a heart attack.
BioVentrix Inc. is developing a unique, minimally invasive approach to reshaping the heart’s scarred and enlarged left ventricle aimed at patients who develop ischemic heart failure following a heart attack. The company has made considerable headway with its technology, which offers an interesting balance between a catheter-based and surgical-based procedure; however, CEO Kenneth Miller, well aware of the pitfalls that have plagued earlier companies in this field, is taking a cautious approach to the US market.
CardioKinetix, maker of a unique, percutaneously placed ventricular partitioning device, and CircuLite, which is developing a less invasive cardiac assist device, are moving into US clinical trials with their technologies – an important milestone for emerging companies in the difficult heart failure space. Both offer therapies aimed at helping fill the huge heart failure treatment gap that exists today.